Why Teva Pharmaceutical (TEVA) Stock Is Lower Today

NEW YORK (TheStreet) -- Teva Pharmaceutical Industries  (TEVA) raised its profit forecast and reported second quarter earnings that beat analyst estimates as its generic division cut costs and a new version of the bestselling Copaxone drug gained traction, Bloomberg reports.

Profit excluding some costs was up 4% to $1.05 billion, or $1.23 a share, from $1.02 billion, or $1.20 a share, a year ago, the company said.

Analysts predicted $1.22, the average of 24 estimates compiled by Bloomberg.

Sales gained 2% to $5 billion, below the average analyst estimate of $5.09 billion.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Shares of Teva Pharmaceutical are down -2.77 to $53.36.

TheStreet Ratings team rates TEVA PHARMACEUTICALS as a Buy with a ratings score of B. TheStreet Ratings Team has this to say about their recommendation:

"We rate TEVA PHARMACEUTICALS (TEVA) a BUY. This is driven by some important positives, which we believe should have a greater impact than any weaknesses, and should give investors a better performance opportunity than most stocks we cover. The company's strengths can be seen in multiple areas, such as its revenue growth, increase in net income, expanding profit margins, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity."

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

S&P 500 and Dow Score Records With Wall Street Upbeat Ahead of Fed

S&P 500 and Dow on Track for Records With Markets in Good Mood Ahead of Fed

S&P 500 and Dow Aim for New Records With Broad-Based Gains Ahead of Fed

Dow and S&P 500 Reach New Intraday Highs With Markets in Good Mood Ahead of Fed

Teva's New CEO Brings This Secret Weapon